Targeting the c-Met/VEGFR Pathway to Boost Nab-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights
Cells · 2026
DOI: 10.3390/cells15030285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Jennifer Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617, USA. Hauptthemen laut MEDLINE: Paclitaxel, Proto-Oncogene Proteins c-met, Stomach Neoplasms, Albumins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Indiana University School of Medicine, Indiana University Medical Student Program for Research and Scholarship.
Abstract (Originalsprache)
Combination chemotherapy regimens are commonly employed to treat advanced gastric adenocarcinoma (GAC), yet median survival remains less than one year. Nab-paclitaxel has demonstrated significant antitumor activity in preclinical GAC models. Overexpression of growth factors and their receptors is prevalent in GAC and contributes to its pathophysiology, with aberrant activation of the HGF/c-Met pathway reported in up to 50% of patients. We hypothesized that merestinib, a small-molecule inhibitor of c-Met, Axl, and DDR1/2, would enhance the therapeutic response to nab-paclitaxel in GAC. In high c-Met–expressing MKN-45 peritoneal dissemination xenografts in female NOD/SCID mouse models, animal survival was 17 days in controls, 37 days with nab-paclitaxel (118% increase), 24 days with merestinib (41% increase), and 43 days with the combination (153% increase), demonstrating significantly enhanced survival compared with either monotherapy. In MKN-45 subcutaneous xenografts, tumor volumes in the control, nab-paclitaxel, merestinib, and combination groups were 503 mm3, 115 mm3, 91 mm3, and −9.7 mm3 (indicating tumor regression), respectively. In low c-Met-expressing SNU-1 xenografts, tumor volumes were 219 mm3, 105 mm3, 131 mm3, and 57 mm3, respectively. IHC analysis of tumor cell proliferation and microvessel density in MKN-45 tumors supported these findings. In vitro, nab-paclitaxel and merestinib each reduced cell proliferation in GAC-associated cells, with enhanced inhibitory effects when used in combination. In MKN-45 cells, merestinib increased the expression of pro-apoptotic proteins and decreased phosphorylation of c-Met, EGFR, IGF-1R, ERK, and AKT. These results indicate that combining merestinib with nab-paclitaxel may represent a promising therapeutic strategy to improve outcomes for patients with GAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617, USA.
- Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46617, USA.
- Goshen Center for Cancer Care, Goshen, IN 46526, USA.
- School of Medicine, University of Basel, CH-4056 Basel, Switzerland.
ORCID-Profile: Quinn Kaurich, Md Sazzad Hassan
Förderung
- NCI NIH HHS
- Indiana University School of Medicine
- Indiana University Medical Student Program for Research and Scholarship
- University of Notre Dame College of Science Summer Undergraduate Research Fellowship
Zitieren
APA
Huang, J., Kaurich, Q., Hassan, M. S., von Holzen, U., & Awasthi, N. (2026). Targeting the c-Met/VEGFR Pathway to Boost Nab-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights. Cells. https://doi.org/10.3390/cells15030285
Vancouver
Huang J, Kaurich Q, Hassan MS, von Holzen U, Awasthi N. Targeting the c-Met/VEGFR Pathway to Boost Nab-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights. Cells. 2026. doi:10.3390/cells15030285
BibTeX
@article{Huang2026,
author = {Huang, Jennifer and Kaurich, Quinn and Hassan, Md Sazzad and von Holzen, Urs and Awasthi, Niranjan},
title = {Targeting the c-Met/VEGFR Pathway to Boost Nab-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15030285}
}
EUVIMED